Quick Dispatch:
Your tirzepatide in adolescents A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide in adolescents A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) ships.
Need Help?
Questions about tirzepatide in adolescents A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2), sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide in adolescents A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) in your area.
LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
29.38
Is Tirzepatide a Diuretic? Understanding the Key Differences
25.79
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
26.73
Tirzepatide's effects on various organs
27.22
SURPASS-PEDS: Tirzepatide Achieves Superiority to Placebo in Adolescent T2D
27.91
01200-X/asset/429e6fd1-61d1-402a-91a5-b2ec86b1b878/main.assets/gr2_lrg.jpg "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial")
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
26.05
Current treatment options for youth-onset type 2 diabetes are limited. A new study investigated the safety and efficacy of tirzepatide compared with placebo in children and adolescents with type 2 diabetes: https://t.co/BZ8As9ucg1 #
29.51
